Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      TERMINATED
      A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
      Description

      The purpose of CTO-IUSCC-0730 study is to assess the clinical efficacy of LY3214996 in combination with abemaciclib at the recommended phase 2 dose of LY3214996 200 mg orally daily and abemaciclib 150 mg orally twice daily. Patients will be treated until evidence of disease progression, non-compliance with study protocol, unacceptable major toxicity, at subject's own request for withdrawal, or if the study closes for any reason.

      Conditions
      CancerCancer MetastaticBRAF V600EMEK1 Gene MutationMEK2 Gene MutationERK MutationRAF1 Gene Mutation
      Talk to us
      ACTIVE_NOT_RECRUITING
      Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors
      Description

      This is a Phase 1b/2, multi-center, open label umbrella study of patients ≥12 years of age with recurrent, progressive, or refractory melanoma or other solid tumors with alterations in the key proteins of the RAS/RAF/MEK/ERK pathway, referred to as the MAPK pathway.

      Conditions
      MelanomaSolid TumorCRAF Gene AmplificationRAF1 Gene AmplificationBRAF Gene FusionBRAF FusionCRAF Gene FusionCRAF FusionRAF1 Gene FusionRAF1 FusionThyroid Cancer, PapillarySpitzoid MelanomaPilocytic AstrocytomaPilocytic Astrocytoma, AdultNon Small Cell Lung CancerNon-Small Cell AdenocarcinomaColorectal CancerPancreatic Acinar CarcinomaSpitzoid Malignant MelanomaBladder CancerBladder Urothelial CarcinomaMAP Kinase Family Gene MutationRAS MutationRAF MutationMEK Mutation
      Talk to us